Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer : Evidence from Seven Randomized Clinical Trials
المؤلفون المشاركون
Chen, Yan Xian
Jiang, Zhi-min
Xie, De-rong
Wei, Ying
Chen, Shi-yu
Kuang, Jun-jie
Yang, Qiong
المصدر
Gastroenterology Research and Practice
العدد
المجلد 2014، العدد 2014 (31 ديسمبر/كانون الأول 2014)، ص ص. 1-8، 8ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2014-05-25
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الملخص EN
Background.
Efficacy of adding bevacizumab in first-line chemotherapy of metastatic colorectal cancer (mCRC) has been controversial.
The aim of this study is to gather current data to analyze efficacy of adding bevacizumab to the most used combination first-line chemotherapy in mCRC, based on the 2012 meta-analysis reported by Macedo et al. Methods.
Medline, EMBASE and Cochrane library, meeting presentations and abstracts were searched.
Eligible studies were randomized controlled trials (RCTs) which evaluated first-line chemotherapy with or without bevacizumab in mCRC.
The extracting data were included and examined in the meta-analysis according to the type of chemotherapy regimen.
Results.
Seven trials, totaling 3436 patients, were analyzed.
Compared with first-line chemothery alone, the adding of bevacizumab did not show clinical benefit for OS both in first-line therapy and the most used combination chemotherapy (HR = 0.89; 95% CI = 0.78–1.02; P=0.08; HR = 0.93; 95% CI = 0.83–1.05; P=0.24).
In contrast with OS, the addition of bevacizumab resulted in significant improvement for PFS (HR = 0.68; 95% CI = 0.59–0.78; P<0.00001).
Moreover, it also demonstrated statistical benefit for PFS in the most used combination first-line chemotherapy (HR = 0.84; 95% CI = 0.75–0.94; P=0.002).
And the subgroup analysis indicated only capacitabine-based regimens were beneficial.
Conclusions.
This meta-analysis shows that the addition of bevacizumab to FOLFOX/FOLFIRI/XELOX regimens might not be beneficial in terms of OS.
Benefit has been seen when PFS has been taken into account.
In subgroup analysis, benefit adding bevacizumab has been seen when capecitabine-based regimens are used.
Further studies are warranted to explore the combination with bevacizumab.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Chen, Yan Xian& Yang, Qiong& Kuang, Jun-jie& Chen, Shi-yu& Wei, Ying& Jiang, Zhi-min…[et al.]. 2014. Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer : Evidence from Seven Randomized Clinical Trials. Gastroenterology Research and Practice،Vol. 2014, no. 2014, pp.1-8.
https://search.emarefa.net/detail/BIM-483673
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Chen, Yan Xian…[et al.]. Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer : Evidence from Seven Randomized Clinical Trials. Gastroenterology Research and Practice No. 2014 (2014), pp.1-8.
https://search.emarefa.net/detail/BIM-483673
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Chen, Yan Xian& Yang, Qiong& Kuang, Jun-jie& Chen, Shi-yu& Wei, Ying& Jiang, Zhi-min…[et al.]. Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer : Evidence from Seven Randomized Clinical Trials. Gastroenterology Research and Practice. 2014. Vol. 2014, no. 2014, pp.1-8.
https://search.emarefa.net/detail/BIM-483673
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-483673
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر